☆ 4.4 Editorial Material

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

DIABETES THERAPY (2022)

Related references

Note: Only part of the references are listed.
Article Endocrinology & Metabolism

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provides clinical practice recommendations and tools to evaluate quality of care. It is updated regularly by a committee of experts.

DIABETES CARE (2022)

Add to Collection
Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Martin R. Cowie et al.

NATURE REVIEWS CARDIOLOGY (2020)

Add to Collection
Review Endocrinology & Metabolism

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Andre J. Scheen

NATURE REVIEWS ENDOCRINOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection
Review Medicine, General & Internal

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker et al.

LANCET (2019)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.